No abstract listed.
Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents
The angiotensin AT2 receptor stimulates protein tyrosine phosphatase activity and mediates inhibition of particulate guanylate cyclase
Impaired inotropic response to alpha 1- but not to beta-adrenoceptor stimulation in isolated hearts from spontaneously hypertensive rats
Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site directed mutagenesis
New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives
Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial?
Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist
Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs
Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives
Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences
Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype
Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II
1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists
Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II
Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term
The discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives
Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review
A unique geometry of the active site of angiotensin-converting enzyme consistent with structure-activity studies
Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm
Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms.
Effects of irbesartan (SR47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action
Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal
Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients
An efficient synthesis of a rationally designed 1,5 disubstituted imidazole AT(1) angiotensin II receptor antagonist: reorientation of imidazole pharmacophore groups in losartan reserves high receptor affinity and confirms docking studies.
Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR-7280
Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment
Molecular cloning and pharmacological characterization of an atypical gerbil angiotensin II type-1 receptor and its mRNA expression in brain and peripheral tissues
Pharmacological characterization of EK112, a new combined angiotensin II and thromboxane A(2) receptor antagonist
Structural comparison between type I and type II antagonists: possible implications in the drug design of AT1 antagonists
Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects
Discovery of 4'-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists
The conformation and activity relationship of benzofuran type of angiotensin II receptor antagonists
Synthesis and study of a cyclic angiotensin II antagonist analogue reveals the role of pi*--pi* interactions in the C-terminal aromatic residue for agonist activity and its structure resemblance with AT(1) non-peptide antagonists
A comparative molecular field analysis and molecular modelling studies on pyridylimidazole type of angiotensin II antagonists
The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ
CROSS: an efficient workflow for reaction-driven rescaffolding and side-chain optimization using robust chemical reactions and available reagents
Highly sensitive and selective Pd2+ sensor of naphthalimide derivative based on complexation with alkynes and thio-heterocycle
Discovery of potent antihypertensive ligands substituted imidazolyl biphenyl sulfonylureas analogs as angiotensin II AT1 receptor antagonists by molecular modelling studies
2-(1H-Benzimidazol-2-yl)-4,5,6,7-tetrahydro-2H-indazol-3-ol, a benzimidazole derivative, inhibits T cell proliferation involving H+/K+-ATPase inhibition.
Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure
WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats
Ligand-supported homology modeling of the human angiotensin II type 1 (AT(1)) receptor: insights into the molecular determinants of telmisartan binding
Discovery of Potent Antihypertensive Ligands Substituted Imidazolyl Biphenyl Sulfonylureas Analogs as Angiotensin II AT1 Receptor Antagonists by Molecular Modelling Studies
Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach
Development of a validated liquid chromatographic method for determination of related substances of telmisartan in bulk drugs and formulations
The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases
Antihypertensive Agents: Mechanisms of Action
Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.